| Symbol | Name | Last Trade Price | Change |
|---|---|---|---|
AMGN Daily Activity
| Open | P/E Ratio | 52 week Range | Percent Change From 52 week High |
|---|---|---|---|
AMGN Dividend Yield Chart
AMGN Dividend Data
| Dividend Yield | Dividend per Share | Ex-Dividend Date | Dividend Pay Date |
|---|---|---|---|
AMGN Amgen Inc. Dividend Yield
AMGN Dividend Payout History Graph
| Symbol | Name | Last Trade Price | Change | Change (%) | Earnings per Share |
|---|---|---|---|---|---|
News headlines for AMGN
AMGN Company Information
| AMGN Description: Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
| AMGN HQ Address: ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA 91320 |
| AMGN Website URL: http://www.amgen.com |
Similar Companies |